Us regulators authorized the use of intranasal spray with esketamine (esketamine) for treatment of patients with clinical depression and suicidal thoughts. Earlier studies have shown that the drug helps to quickly deal with thoughts of suicide and to alleviate the symptoms of depression, says MedicalXpress.
Intranasal spray with esketamine (trade name Stravato) was originally registered with the FDA in March 2019 for use in patients with depression resistant to other therapies. Since the drug was administered at approximately 6, thousand patients.
One of the features of an intranasal spray is fast acting: within 4 hours after application esketamine have noted improvements in the patients ‘ condition. The effect of standard treatment occurs in 6-8 weeks, and this is a very long time, especially if we are talking about the risk of suicide.